Intravascular ultrasound results from the NEVO ResElution-I trial: a randomized, blinded comparison of sirolimus-eluting NEVO stents with paclitaxel-eluting TAXUS Liberté stents in de novo native coronary artery lesions.

Abstract

BACKGROUND:

The NEVO sirolimus-eluting stent (NEVO SES) is a novel cobalt-chromium stent combining sirolimus release from reservoirs with bioabsorbable polymer to reduce spatial and temporal polymer exposure. The aim of this study was to assess the arterial response to the NEVO SES in a randomized, blinded comparison versus the surface-coated TAXUS Liberte paclitaxel-eluting stent (TAXUS Liberté PES) in human native coronary lesions using intravascular ultrasound (IVUS).

METHODS AND RESULTS:

The NEVO ResElution-I IVUS substudy enrolled 100 patients (1:1 randomization). In addition to standard IVUS variables, uniformity of neointimal distribution within stents was evaluated in 3 dimensions by computing mean neointimal thickness within 12 equally spaced radial sectors on every 1-mm cross section along the stented segment. The NEVO SES showed significantly less neointimal proliferation (neointimal obstruction: 5.5±11.0% versus 11.5±9.7%, P=0.02), resulting in less late lumen area loss and smaller maximum cross-sectional narrowing at 6 months. The absolute variability of neointima distribution, assessed by the standard deviation of neointimal thickness within each stent, was significantly reduced with the NEVO SES compared with the TAXUS Liberté PES(0.04±0.04 mm versus 0.10±0.07 mm, P<0.0001). TAXUS Liberté PES showed significantly greater positive vessel remodeling than the NEVO SES (Δvessel volume index: 1.30±1.36 mm(3)/mm versus 0.36±0.63 mm(3)/mm, respectively, P=0.003).

CONCLUSIONS:

The NEVO SES with focal release of sirolimus from reservoirs achieved significantly greater and more consistent suppression of neointimal hyperplasia than the surface-coated TAXUS Liberté PES. This was associated with less positive remodeling and no increased morphological or morphometric abnormalities surrounding the stent or at the stent margins.

CLINICAL TRIAL REGISTRATION:

URL: http://www.clinicaltrials.gov. Unique identifier: NCT00714883.

• Authors: Hiromasa Otake, Yasuhiro Honda, Brian K Courtney, Takao Shimohama, Junya Ako, Katsuhisa Waseda, Nathalie Macours, Campbell Rogers, Jeffrey J Popma, Alexandre Abizaid, John A Ormiston, Christian Spaulding, Sidney A Cohen, Peter J Fitzgerald
• Journal: Circulation. Cardiovascular interventions (Circ Cardiovasc Interv) Vol. 4 Issue 2 Pg. 146-54 (Apr 01 2011) ISSN: 1941-7632 [Electronic] United States
• PMID: 21386089 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: © 2011 American Heart Association, Inc.

Chemical References

• Paclitaxel
• Sirolimus

Topics

• Aged
• Angioplasty, Balloon, Coronary
• Coronary Angiography
• Coronary Artery Disease (diagnostic imaging, therapy)
• Drug-Eluting Stents
• Female
• Humans
• Hyperplasia
• Male
• Middle Aged
• Neointima (pathology)
• Paclitaxel (administration & dosage)
• Prospective Studies
• Single-Blind Method
• Sirolimus (administration & dosage)
• Ultrasonography, Interventional